



April 6<sup>th</sup>, 2015

Dear Association for Creatine Deficiencies Board Members and Friends,

As the CEO of Lumos Pharma, Allow me to personally congratulate the ACD for their important work in advocating for patients with Creatine Deficiencies.

The ACD's efforts to raise awareness and organize the community are critical steps toward improving the lives of patients and families affected by these disorders. Additionally, the Association's Patient Registry is a significant undertaking, which will provide critical information about Creatine Deficiencies to the community at large.

I would also like to share with you some information about Lumos Pharma, which was founded in 2011 with the sole mission of developing a therapeutic for Creatine Transporter Deficiency (CTD). Last January, we achieved a significant milestone when we completed our Series A financing round. These funds are being used to advance our development program through the preclinical stage (developing the pharmaceutical product, and the required safety testing in animals) and into the early clinical stage (safety and pharmacokinetic testing healthy volunteers). Once these critical steps have been achieved, studies in CTD patients can begin.

We are fortunate to be partnered with the National Institutes of Health's (NIH) Therapeutics for Rare and Neglected Diseases (TRND) program, which provides critical scientific support to accelerate early stage drug development. As part of the TRND program, the NIH is planning a Natural History Study of CTD in 2015. If you are interested in more information about the upcoming NIH study, please discuss with your physician. Lumos' program has also been granted Orphan Drug Designation, which will streamline and accelerate the standard regulatory pathway and timelines.

The process of drug development is an arduous task that can be fraught with many challenges, therefore, we ask for your support and patience as we advance our development program. Lumos Pharma will endeavor to keep the Creatine Deficiency Community informed of our progress through the Association and communication with physicians involved in the care of patients with Creatine Transporter Deficiency.

I have put together a dedicated team of experienced professionals at Lumos Pharma and we all share your sense of urgency in bringing forward meaningful therapeutic options for those affected by CTD.

Thank you and best wishes,

A handwritten signature in blue ink, appearing to read "Richard J. Hawkins".

Richard J. Hawkins  
President and CEO  
Lumos Pharma, Inc